FDA Drug Safety Communication: Important safety changes to the influenza drug Tamiflu (oseltamivir phosphate) for oral suspension

On 7/11/2011, the U.S. Food and Drug Administration (FDA) informed the public of important product safety changes to the influenza drug Tamiflu (oseltamivir phosphate) for oral suspension.

Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news